

### HYTN ENGAGES INDEPENDENT TRADING GROUP AS MARKET MAKER

Vancouver, British Columbia – May 31, 2024 - HYTN Innovations Inc. ("HYTN" or the "Company") (CSE: HYTN), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, is pleased to announce that it has engaged the services of Independent Trading Group ("ITG") as a market maker for its shares traded on the Canadian Securities Exchange ("CSE").

ITG, a leading Canadian broker-dealer, offers liquidity and execution services to clients globally. As a market maker for HYTN, ITG is committed to enhancing liquidity and maintaining a fair and orderly market for HYTN's shares. In accordance with CSE policies, ITG will buy and sell HYTN's shares on the CSE and other alternative Canadian trading venues.

ITG is a wholly owned subsidiary of DVX Capital Markets. The contract with ITG is for an initial 1-month period, with automatic monthly extensions thereafter for a monthly fee of CDN \$5,000, ITG will not receive shares or options as compensation for its services. ITG and HYTN are unrelated and unaffiliated entities and, at the time of the agreement for ITG's services, to the knowledge of the Company, neither ITG nor its principals have an interest, directly or indirectly, in the securities of the Company.

### **About Independent Trading Group**

Independent Trading Group, Inc. is a Toronto based IIROC dealer-member that specializes in market making, liquidity provision, agency execution, ultra-low latency connectivity, and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors.

### **About HYTN Innovations Inc.**

HYTN formulates, manufactures, markets, and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN's mission is to become the top provider of these products in all markets where such products are federally regulated. To achieve this, the Company focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

# For more information, contact:

Elliot McKerr Chief Executive Officer 1.866.590.9289

HYTN Investor Relations 1.866.590.9289

# **Cautionary Note Regarding Forward-Looking Statements**

Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the Company's pursuit of its ambitious goals in the upcoming year. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company's business include, among other things: the Company's ability to generate sufficient cash flow from operations to meet its current and future obligations; the Company's ability to access sources of debt and equity capital; competitive factors, pricing pressures, and supply and demand in the Company's industry; general economic and business conditions; and the effects and impacts of the COVID-19 pandemic, the extent and duration of which are uncertain at this time, on the Company's business and general economic and business conditions and markets. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.

The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.